Compare Stocks: OKUR, TECX, CAPR, and PROK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$9.28 -6.2%	$12.86	$2.96 ▼ $40.37	$574.99M	0.72	11.75 million shs	4.06 million shs
OKUR OnKure Therapeutics	$3.56 +0.6%	$4.10	$2.23 ▼ $5.38	$143M	0.23	149,968 shs	132,190 shs
PROK ProKidney	$1.92 +0.5%	$1.67	$1.30 ▼ $3.48	$577.44M	1.7	1.20 million shs	751,207 shs
TECX Tectonic Therapeutic	$29.92 -1.5%	$33.14	$14.39 ▼ $39.53	$593.91M	3.31	247,563 shs	140,381 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	-6.17%	-7.75%	+122.54%	-65.26%	+47.77%
OKUR OnKure Therapeutics	+0.56%	-7.05%	-13.17%	-15.04%	+25.80%
PROK ProKidney	+0.52%	+5.49%	+17.79%	+6.67%	-18.64%
TECX Tectonic Therapeutic	-1.51%	-18.47%	+2.57%	+3.17%	+83.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$9.28 -6.2%	$12.86	$2.96 ▼ $40.37	$574.99M	0.72	11.75 million shs	4.06 million shs
OKUR OnKure Therapeutics	$3.56 +0.6%	$4.10	$2.23 ▼ $5.38	$143M	0.23	149,968 shs	132,190 shs
PROK ProKidney	$1.92 +0.5%	$1.67	$1.30 ▼ $3.48	$577.44M	1.7	1.20 million shs	751,207 shs
TECX Tectonic Therapeutic	$29.92 -1.5%	$33.14	$14.39 ▼ $39.53	$593.91M	3.31	247,563 shs	140,381 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	-6.17%	-7.75%	+122.54%	-65.26%	+47.77%
OKUR OnKure Therapeutics	+0.56%	-7.05%	-13.17%	-15.04%	+25.80%
PROK ProKidney	+0.52%	+5.49%	+17.79%	+6.67%	-18.64%
TECX Tectonic Therapeutic	-1.51%	-18.47%	+2.57%	+3.17%	+83.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.18	Hold	$29.15	214.12% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	391.57% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	525.00% Upside
TECX Tectonic Therapeutic	2.88	Moderate Buy	$77.25	158.19% Upside

Current Analyst Ratings Breakdown

Latest OKUR, TECX, CAPR, and PROK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	TECX Tectonic Therapeutic	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/18/2026	TECX Tectonic Therapeutic	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	OKUR OnKure Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$14.00
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/7/2026	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$101.00 ➝ $93.00
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.50

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	24.23	N/A	N/A	$4.24 per share	2.19
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.26 per share	N/A
PROK ProKidney	$890K	652.20	N/A	N/A	($2.92) per share	-0.66
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$11.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)
TECX Tectonic Therapeutic	-$74.15M	-$4.57	N/A	N/A	N/A	N/A	-35.26%	-33.59%	11/5/2026 (Estimated)

Latest OKUR, TECX, CAPR, and PROK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million
8/6/2026	Q2 2026	TECX Tectonic Therapeutic	-$1.35	-$1.18	+$0.17	-$1.18	N/A	N/A
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	7.35	7.35
OKUR OnKure Therapeutics	N/A	26.75	26.75
PROK ProKidney	N/A	8.36	8.36
TECX Tectonic Therapeutic	N/A	22.29	22.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
OKUR OnKure Therapeutics	90.98%
PROK ProKidney	51.59%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
OKUR OnKure Therapeutics	2.17%
PROK ProKidney	39.83%
TECX Tectonic Therapeutic	39.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	101	58.14 million	52.79 million	Optionable
OKUR OnKure Therapeutics	N/A	40.40 million	39.52 million	N/A
PROK ProKidney	3	302.32 million	181.91 million	Optionable
TECX Tectonic Therapeutic	120	19.55 million	11.77 million	N/A

OKUR, TECX, CAPR, and PROK Headlines

Recent News About These Companies

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

September 3 at 8:00 AM | globenewswire.com

Braidwell LP Cuts Stake in Tectonic Therapeutic, Inc. $TECX

September 3 at 4:23 AM | marketbeat.com

BlackRock Inc. Makes New Investment in Tectonic Therapeutic, Inc. $TECX

September 2 at 3:35 AM | marketbeat.com

Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case

September 2 at 2:00 AM | seekingalpha.com

Tectonic Therapeutic (NASDAQ:TECX) Shares Up 5.4% - What's Next?

September 1 at 3:39 PM | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 1 at 4:13 AM | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Shares Down 8.4% - What's Next?

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $2.23 Million in Tectonic Therapeutic, Inc. $TECX

August 30, 2026 | marketbeat.com

606,660 Shares in Tectonic Therapeutic, Inc. $TECX Purchased by 5AM Venture Management LLC

August 26, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Zacks Research

August 20, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Trading 5.6% Higher - Should You Buy?

August 18, 2026 | marketbeat.com

Stifel Nicolaus Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)

August 13, 2026 | theglobeandmail.com

Tectonic Therapeutic (NASDAQ:TECX) Trading Up 13.3% - Here's What Happened

August 12, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded by Wall Street Zen to "Sell" Rating

August 8, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), InflaRx (IFRX) and Tectonic Therapeutic (TECX)

August 7, 2026 | theglobeandmail.com

Tectonic Therapeutic (NASDAQ:TECX) Announces Earnings Results, Beats Estimates By $0.17 EPS

August 7, 2026 | marketbeat.com

Wells Fargo & Company Issues Pessimistic Forecast for Tectonic Therapeutic (NASDAQ:TECX) Stock Price

August 7, 2026 | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 7, 2026 | marketbeat.com

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026 | finance.yahoo.com

Tectonic Therapeutic Inc

July 2, 2026 | edition.cnn.com

Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.05%

June 30, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, TECX, CAPR, and PROK Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$9.28 -0.61 (-6.17%)

As of 09/3/2026 04:00 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

OnKure Therapeutics NASDAQ:OKUR

$3.56 +0.02 (+0.56%)

As of 09/3/2026 04:00 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

ProKidney NASDAQ:PROK

$1.92 +0.01 (+0.52%)

As of 09/3/2026 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tectonic Therapeutic NASDAQ:TECX

$29.92 -0.46 (-1.51%)

As of 09/3/2026 04:00 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, TECX, CAPR, and PROK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, TECX, CAPR, and PROK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, TECX, CAPR, and PROK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, TECX, CAPR, and PROK Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

OnKure Therapeutics NASDAQ:OKUR

ProKidney NASDAQ:PROK

Tectonic Therapeutic NASDAQ:TECX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, TECX, CAPR, and PROK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, TECX, CAPR, and PROK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, TECX, CAPR, and PROK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, TECX, CAPR, and PROK Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

OnKure Therapeutics NASDAQ:OKUR

ProKidney NASDAQ:PROK

Tectonic Therapeutic NASDAQ:TECX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools